폐암 진단약 시장, 진단 검사 유형 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Lung Cancer Diagnostics Market - Scope of Report

TMR's report on the global lung cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global lung cancer diagnostics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lung cancer diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the lung cancer diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lung cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lung cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lung cancer diagnostics market.

The report delves into the competitive landscape of the global lung cancer diagnostics market. Key players operating in the global lung cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lung cancer diagnostics market profiled in this report.

Key Questions Answered in Global lung cancer diagnostics Market Report:

• What is the sales/revenue generated by lung cancer diagnostics across all regions during the forecast period?
• What are the opportunities in the global lung cancer diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Lung Cancer Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global lung cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global lung cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lung cancer diagnostics market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Lung Cancer Diagnostics Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Lung Cancer Diagnostics Market Analysis and Forecasts, 2020-2034
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Recent Technological Advancements in Lung Cancer Diagnostics Industry
• 5.2. Insights on Emergence of Liquid Biopsy as a Lung Cancer Diagnostic Tool
• 5.3. Lung Cancer Diagnostics Pricing Trends
• 5.4. Regulatory Landscape across Key Regions / Countries
• 5.5. PORTER's Five Forces Analysis
• 5.6. PESTEL Analysis
• 5.7. Value Chain Analysis
• 5.8. Go-To Market Strategy for New Entrants
• 5.9. Key Purchase Metrics for End-users
• 5.10. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions, funding and investments)
• 5.11. Benchmarking of the Products Offered by the Competitors

6. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Diagnostic Test Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Diagnostic Test Type, 2020-2034
  • 6.3.1. Biopsy
    • 6.3.1.1. Needle biopsy
    • 6.3.1.2. Transbronchial biopsy
    • 6.3.1.3. Thoracoscopic biopsy
    • 6.3.1.4. Liquid Biopsy
      • 6.3.1.4.1. Circulating Tumor Cells (CTCs)
      • 6.3.1.4.2. Circulating Tumor DNA
      • 6.3.1.4.3. Cell-Free RNA (cfRNA)
      • 6.3.1.4.4. Exosomes
      • 6.3.1.4.5. Proteomic Analysis
    • 6.3.1.5. Others
  • 6.3.2. Imaging Tests
    • 6.3.2.1. Magnetic Resonance Imaging (MRI)
    • 6.3.2.2. Computed Tomography (CT) Scan
    • 6.3.2.3. Chest Ultrasound
    • 6.3.2.4. Positron Emission Tomography (PET)
    • 6.3.2.5. Other Imaging Tests
  • 6.3.3. Molecular Testing
  • 6.3.4. Others
• 6.4. Market Attractiveness By Diagnostic Test Type

7. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Product Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Product Type, 2020-2034
  • 7.3.1. Instruments
  • 7.3.2. Consumables
• 7.4. Market Attractiveness By Product Type

8. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Cancer Type

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Cancer Type, 2020-2034
  • 8.3.1. Non-small cell lung cancer (NSCLC)
  • 8.3.2. Small cell lung cancer (SCLC)
• 8.4. Market Attractiveness By Cancer Type

9. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By End-user

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By End-user, 2020-2034
  • 9.3.1. Hospitals
  • 9.3.2. Clinics
  • 9.3.3. Diagnostic & Imaging Centers
  • 9.3.4. Cancer Research Institutes
• 9.4. Market Attractiveness By End-user

10. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Region

• 10.1. Key Findings
• 10.2. Market Value Forecast By Region
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness By Region

11. North America Lung Cancer Diagnostics Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
  • 11.2.1. Biopsy
    • 11.2.1.1. Needle biopsy
    • 11.2.1.2. Transbronchial biopsy
    • 11.2.1.3. Thoracoscopic biopsy
    • 11.2.1.4. Liquid Biopsy
      • 11.2.1.4.1. Circulating Tumor Cells (CTCs)
      • 11.2.1.4.2. Circulating Tumor DNA
      • 11.2.1.4.3. Cell-Free RNA (cfRNA)
      • 11.2.1.4.4. Exosomes
      • 11.2.1.4.5. Proteomic Analysis
    • 11.2.1.5. Others
  • 11.2.2. Imaging Tests
    • 11.2.2.1. Magnetic Resonance Imaging (MRI)
    • 11.2.2.2. Computed Tomography (CT) Scan
    • 11.2.2.3. Chest Ultrasound
    • 11.2.2.4. Positron Emission Tomography (PET)
    • 11.2.2.5. Other Imaging Tests
  • 11.2.3. Molecular Testing
  • 11.2.4. Others
• 11.3. Market Value Forecast By Product Type, 2020-2034
  • 11.3.1. Instruments
  • 11.3.2. Consumables
• 11.4. Market Value Forecast By Cancer Type, 2020-2034
  • 11.4.1. Non-small cell lung cancer (NSCLC)
  • 11.4.2. Small cell lung cancer (SCLC)
• 11.5. Market Value Forecast By End-user, 2020-2034
  • 11.5.1. Hospitals
  • 11.5.2. Clinics
  • 11.5.3. Diagnostic & Imaging Centers
  • 11.5.4. Cancer Research Institutes
• 11.6. Market Value Forecast By Country, 2020-2034
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Diagnostic Test Type
  • 11.7.2. By Product Type
  • 11.7.3. By Cancer Type
  • 11.7.4. By End-user
  • 11.7.5. By Country

12. Europe Lung Cancer Diagnostics Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
  • 12.2.1. Biopsy
    • 12.2.1.1. Needle biopsy
    • 12.2.1.2. Transbronchial biopsy
    • 12.2.1.3. Thoracoscopic biopsy
    • 12.2.1.4. Liquid Biopsy
      • 12.2.1.4.1. Circulating Tumor Cells (CTCs)
      • 12.2.1.4.2. Circulating Tumor DNA
      • 12.2.1.4.3. Cell-Free RNA (cfRNA)
      • 12.2.1.4.4. Exosomes
      • 12.2.1.4.5. Proteomic Analysis
    • 12.2.1.5. Others
  • 12.2.2. Imaging Tests
    • 12.2.2.1. Magnetic Resonance Imaging (MRI)
    • 12.2.2.2. Computed Tomography (CT) Scan
    • 12.2.2.3. Chest Ultrasound
    • 12.2.2.4. Positron Emission Tomography (PET)
    • 12.2.2.5. Other Imaging Tests
  • 12.2.3. Molecular Testing
  • 12.2.4. Others
• 12.3. Market Value Forecast By Product Type, 2020-2034
  • 12.3.1. Instruments
  • 12.3.2. Consumables
• 12.4. Market Value Forecast By Cancer Type, 2020-2034
  • 12.4.1. Non-small cell lung cancer (NSCLC)
  • 12.4.2. Small cell lung cancer (SCLC)
• 12.5. Market Value Forecast By End-user, 2020-2034
  • 12.5.1. Hospitals
  • 12.5.2. Clinics
  • 12.5.3. Diagnostic & Imaging Centers
  • 12.5.4. Cancer Research Institutes
• 12.6. Market Value Forecast By Country / Sub-region, 2020-2034
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Spain
  • 12.6.5. Italy
  • 12.6.6. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Diagnostic Test Type
  • 12.7.2. By Product Type
  • 12.7.3. By Cancer Type
  • 12.7.4. By End-user
  • 12.7.5. By Country / Sub-region

13. Asia Pacific Lung Cancer Diagnostics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
  • 13.2.1. Biopsy
    • 13.2.1.1. Needle biopsy
    • 13.2.1.2. Transbronchial biopsy
    • 13.2.1.3. Thoracoscopic biopsy
    • 13.2.1.4. Liquid Biopsy
      • 13.2.1.4.1. Circulating Tumor Cells (CTCs)
      • 13.2.1.4.2. Circulating Tumor DNA
      • 13.2.1.4.3. Cell-Free RNA (cfRNA)
      • 13.2.1.4.4. Exosomes
      • 13.2.1.4.5. Proteomic Analysis
    • 13.2.1.5. Others
  • 13.2.2. Imaging Tests
    • 13.2.2.1. Magnetic Resonance Imaging (MRI)
    • 13.2.2.2. Computed Tomography (CT) Scan
    • 13.2.2.3. Chest Ultrasound
    • 13.2.2.4. Positron Emission Tomography (PET)
    • 13.2.2.5. Other Imaging Tests
  • 13.2.3. Molecular Testing
  • 13.2.4. Others
• 13.3. Market Value Forecast By Product Type, 2020-2034
  • 13.3.1. Instruments
  • 13.3.2. Consumables
• 13.4. Market Value Forecast By Cancer Type, 2020-2034
  • 13.4.1. Non-small cell lung cancer (NSCLC)
  • 13.4.2. Small cell lung cancer (SCLC)
• 13.5. Market Value Forecast By End-user, 2020-2034
  • 13.5.1. Hospitals
  • 13.5.2. Clinics
  • 13.5.3. Diagnostic & Imaging Centers
  • 13.5.4. Cancer Research Institutes
• 13.6. Market Value Forecast By Country / Sub-region, 2020-2034
  • 13.6.1. China
  • 13.6.2. Japan
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Diagnostic Test Type
  • 13.7.2. By Product Type
  • 13.7.3. By Cancer Type
  • 13.7.4. By End-user
  • 13.7.5. By Country / Sub-region

14. Latin America Lung Cancer Diagnostics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
  • 14.2.1. Biopsy
    • 14.2.1.1. Needle biopsy
    • 14.2.1.2. Transbronchial biopsy
    • 14.2.1.3. Thoracoscopic biopsy
    • 14.2.1.4. Liquid Biopsy
      • 14.2.1.4.1. Circulating Tumor Cells (CTCs)
      • 14.2.1.4.2. Circulating Tumor DNA
      • 14.2.1.4.3. Cell-Free RNA (cfRNA)
      • 14.2.1.4.4. Exosomes
      • 14.2.1.4.5. Proteomic Analysis
    • 14.2.1.5. Others
  • 14.2.2. Imaging Tests
    • 14.2.2.1. Magnetic Resonance Imaging (MRI)
    • 14.2.2.2. Computed Tomography (CT) Scan
    • 14.2.2.3. Chest Ultrasound
    • 14.2.2.4. Positron Emission Tomography (PET)
    • 14.2.2.5. Other Imaging Tests
  • 14.2.3. Molecular Testing
  • 14.2.4. Others
• 14.3. Market Value Forecast By Product Type, 2020-2034
  • 14.3.1. Instruments
  • 14.3.2. Consumables
• 14.4. Market Value Forecast By Cancer Type, 2020-2034
  • 14.4.1. Non-small cell lung cancer (NSCLC)
  • 14.4.2. Small cell lung cancer (SCLC)
• 14.5. Market Value Forecast By End-user, 2020-2034
  • 14.5.1. Hospitals
  • 14.5.2. Clinics
  • 14.5.3. Diagnostic & Imaging Centers
  • 14.5.4. Cancer Research Institutes
• 14.6. Market Value Forecast By Country / Sub-region, 2020-2034
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Diagnostic Test Type
  • 14.7.2. By Product Type
  • 14.7.3. By Cancer Type
  • 14.7.4. By End-user
  • 14.7.5. By Country / Sub-region

15. Middle East & Africa Lung Cancer Diagnostics Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
  • 15.2.1. Biopsy
    • 15.2.1.1. Needle biopsy
    • 15.2.1.2. Transbronchial biopsy
    • 15.2.1.3. Thoracoscopic biopsy
    • 15.2.1.4. Liquid Biopsy
      • 15.2.1.4.1. Circulating Tumor Cells (CTCs)
      • 15.2.1.4.2. Circulating Tumor DNA
      • 15.2.1.4.3. Cell-Free RNA (cfRNA)
      • 15.2.1.4.4. Exosomes
      • 15.2.1.4.5. Proteomic Analysis
    • 15.2.1.5. Others
  • 15.2.2. Imaging Tests
    • 15.2.2.1. Magnetic Resonance Imaging (MRI)
    • 15.2.2.2. Computed Tomography (CT) Scan
    • 15.2.2.3. Chest Ultrasound
    • 15.2.2.4. Positron Emission Tomography (PET)
    • 15.2.2.5. Other Imaging Tests
  • 15.2.3. Molecular Testing
  • 15.2.4. Others
• 15.3. Market Value Forecast By Product Type, 2020-2034
  • 15.3.1. Instruments
  • 15.3.2. Consumables
• 15.4. Market Value Forecast By Cancer Type, 2020-2034
  • 15.4.1. Non-small cell lung cancer (NSCLC)
  • 15.4.2. Small cell lung cancer (SCLC)
• 15.5. Market Value Forecast By End-user, 2020-2034
  • 15.5.1. Hospitals
  • 15.5.2. Clinics
  • 15.5.3. Diagnostic & Imaging Centers
  • 15.5.4. Cancer Research Institutes
• 15.6. Market Value Forecast By Country / Sub-region, 2020-2034
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Diagnostic Test Type
  • 15.7.2. By Product Type
  • 15.7.3. By Cancer Type
  • 15.7.4. By End-user
  • 15.7.5. By Country / Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 16.2. Market Share Analysis By Company (2023)
• 16.3. Company Profiles
  • 16.3.1. Abbott
    • 16.3.1.1. Company Overview
    • 16.3.1.2. Financial Overview
    • 16.3.1.3. Product Portfolio
    • 16.3.1.4. Business Strategies
    • 16.3.1.5. Recent Developments
  • 16.3.2. Siemens Healthcare
    • 16.3.2.1. Company Overview
    • 16.3.2.2. Financial Overview
    • 16.3.2.3. Product Portfolio
    • 16.3.2.4. Business Strategies
    • 16.3.2.5. Recent Developments
  • 16.3.3. GE Healthcare
    • 16.3.3.1. Company Overview
    • 16.3.3.2. Financial Overview
    • 16.3.3.3. Product Portfolio
    • 16.3.3.4. Business Strategies
    • 16.3.3.5. Recent Developments
  • 16.3.4. Amoy Diagnostics Co.
    • 16.3.4.1. Company Overview
    • 16.3.4.2. Financial Overview
    • 16.3.4.3. Product Portfolio
    • 16.3.4.4. Business Strategies
    • 16.3.4.5. Recent Developments
  • 16.3.5. Boditech Med, Inc.
    • 16.3.5.1. Company Overview
    • 16.3.5.2. Financial Overview
    • 16.3.5.3. Product Portfolio
    • 16.3.5.4. Business Strategies
    • 16.3.5.5. Recent Developments
  • 16.3.6. Danaher
    • 16.3.6.1. Company Overview
    • 16.3.6.2. Financial Overview
    • 16.3.6.3. Product Portfolio
    • 16.3.6.4. Business Strategies
    • 16.3.6.5. Recent Developments
  • 16.3.7. F. Hoffmann-La Roche
    • 16.3.7.1. Company Overview
    • 16.3.7.2. Financial Overview
    • 16.3.7.3. Product Portfolio
    • 16.3.7.4. Business Strategies
    • 16.3.7.5. Recent Developments
  • 16.3.8. INOVIQ
    • 16.3.8.1. Company Overview
    • 16.3.8.2. Financial Overview
    • 16.3.8.3. Product Portfolio
    • 16.3.8.4. Business Strategies
    • 16.3.8.5. Recent Developments
  • 16.3.9. MedGenome
    • 16.3.9.1. Company Overview
    • 16.3.9.2. Financial Overview
    • 16.3.9.3. Product Portfolio
    • 16.3.9.4. Business Strategies
    • 16.3.9.5. Recent Developments
  • 16.3.10. Quest Diagnostics Incorporated
    • 16.3.10.1. Company Overview
    • 16.3.10.2. Financial Overview
    • 16.3.10.3. Product Portfolio
    • 16.3.10.4. Business Strategies
    • 16.3.10.5. Recent Developments
  • 16.3.11. DiaSorin S.p.A.
    • 16.3.11.1. Company Overview
    • 16.3.11.2. Financial Overview
    • 16.3.11.3. Product Portfolio
    • 16.3.11.4. Business Strategies
    • 16.3.11.5. Recent Developments
  • 16.3.12. Oncocyte Corporation
    • 16.3.12.1. Company Overview
    • 16.3.12.2. Financial Overview
    • 16.3.12.3. Product Portfolio
    • 16.3.12.4. Business Strategies
    • 16.3.12.5. Recent Developments
  • 16.3.13. QIAGEN
    • 16.3.13.1. Company Overview
    • 16.3.13.2. Financial Overview
    • 16.3.13.3. Product Portfolio
    • 16.3.13.4. Business Strategies
    • 16.3.13.5. Recent Developments
  • 16.3.14. Thermo Fisher Scientific, Inc.
    • 16.3.14.1. Company Overview
    • 16.3.14.2. Financial Overview
    • 16.3.14.3. Product Portfolio
    • 16.3.14.4. Business Strategies
    • 16.3.14.5. Recent Developments
  • 16.3.15. NanoString Technologies
    • 16.3.15.1. Company Overview
    • 16.3.15.2. Financial Overview
    • 16.3.15.3. Product Portfolio
    • 16.3.15.4. Business Strategies
    • 16.3.15.5. Recent Developments
  • 16.3.16. Biodesix
    • 16.3.16.1. Company Overview
    • 16.3.16.2. Financial Overview
    • 16.3.16.3. Product Portfolio
    • 16.3.16.4. Business Strategies
    • 16.3.16.5. Recent Developments
  • 16.3.17. Other Prominent Players
    • 16.3.17.1. Company Overview
    • 16.3.17.2. Financial Overview
    • 16.3.17.3. Product Portfolio
    • 16.3.17.4. Business Strategies
    • 16.3.17.5. Recent Developments